Exploiting And Defining The Immune Regulatory Activities Of BET Bromodomain Inhibitors
Funder
National Health and Medical Research Council
Funding Amount
$128,224.00
Summary
Immune-based agents such as “checkpoint inhibitors” have the ability to re-awaken our own immune systems and activate previously dormant anti-tumour responses. We have discovered that small molecule inhibitors of gene regulatory proteins called bromodomain proteins act synergistically with checkpoint inhibitors in mouse cancer models. I will define the molecular and biological events underpinning this novel combination approach and assess the effects of the combination across different tumours.
CD300f As A Novel Therapeutic Antibody Target In Acute Myeloid Leukaemia
Funder
National Health and Medical Research Council
Funding Amount
$89,926.00
Summary
This study aims to develop a new antibody therapy for Acute Myeloid Leukaemia (AML), the most common type of leukaemia in adults. We will study the function of CD300f, a new receptor found on the surface of both healthy blood cells and the cancer cells in AML. We will investigate whether blocking this receptor with a newly developed antibody can be used to kill cancer cells. It is hoped that this study will allow development of this antibody for use in a future clinical trial.